Syndax Pharmaceuticals Reports Inducement Grants

Got story updates? Submit your updates here. ›

Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company, announced that on April 1, 2026, it granted inducement awards to purchase up to 228,500 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax.

Why it matters

Syndax is a leading biopharmaceutical company focused on developing innovative cancer therapies. The announcement of these inducement grants highlights the company's continued growth and investment in expanding its team to advance its pipeline of cancer treatments.

The details

The inducement awards granted by Syndax Pharmaceuticals include stock options to purchase up to 228,500 shares of the company's common stock. These options will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the remaining shares vesting monthly over the following 36 months, contingent on the employees' continued service with the company.

• Syndax Pharmaceuticals announced the inducement grants on April 3, 2026.
• The stock options were granted on April 1, 2026.